Parkinson Disease
Conditions
Brief summary
* Determine clinical characteristics of parkinsonian patients in various stages of disease; * Measure peripheral neurodegeneration, synaptic, and inflammation biomarkers in a population of parkinsonian patients at various stages of disease. * Measure vesicular neurodegeneration, synaptic and inflammation biomarkers
Interventions
PROCEDUREblood sample
blood sample
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with idiopathic PD according to Movement Disorders Society (MDS) criteria; * Age: 18-80 years; * Signature of informed consent to participate in this study
Exclusion criteria
. * Women pregnant * Inflammatory or autoimmune diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine clinical characteristics of parkinsonian patients in various stages of disease | 3 years | Determine clinical characteristics of parkinsonian patients in various stages of disease by means of MDS-UPDRS score changes. |
| Determine biooogical characteristics of parkinsonian patients in various stages of disease | 3 years | dosage of serum IL-1b, IL6, IL-5, IL-4, IL17, TNFa, IFNg, IL10, total-alpha-synuclein, NfL, BDNF (ng/ml for all) |
Countries
Italy
Contacts
Primary ContactGiulia Di Lazzaro, MD
Backup ContactFlavia Torlizzi
Outcome results
None listed